Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

x assets and related valuation allowance) and liabilities of Old Lorus were transferred to the Company and/or its subsidiaries. The Company continued the business of Old Lorus after the Arrangement Date with the same officers and employees and continued to be governed by the same Board of Directors as Old Lorus prior to the Arrangement Date. Therefore, the Company's operations have been accounted for on a continuity of interest basis and accordingly, the consolidated financial statement information above reflect that of the Company as if it had always carried on the business formerly carried on by Old Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us ar
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... , ... Kuantan, Malaysia facility awarded ISO13485 medical manufacturing certification. , ... Weybridge, United Kingdom (PRWEB) January ... today that its manufacturing facility in Kuantan, Malaysia has received ISO 13485:2003 medical ...
... , WASHINGTON , Jan. 22 The Advisory Board ... conference call hosted by Robert W. Musslewhite , Chief Executive Officer ... Company,s financial results for the quarter ended December 31, 2009 . ... at 6:00 p.m., Eastern Time .  The Company plans to release ...
... , , Twenty leading US ... the benefits of NIH funding through the 2009 Recovery and ... In advance of the one-year anniversary of the ... twenty of the nation,s leading research institutions, patient advocates and ...
Cached Biology Technology:All TT Electronics Integrated Manufacturing Services Facilities Accredited with Medical Manufacturing Standard 2The Advisory Board Company Schedules Third Quarter Conference Call for February 4, 2010 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 3
(Date:4/22/2014)... from NeuroPhage Pharmaceuticals, Inc. have engineered a series ... neurodegenerative diseases that are characterized by misfolded proteins, ... molecules are based on what the Company calls ... recognizes a characteristic common to many toxic, misfolded ... This approach provides NeuroPhage with an array of ...
(Date:4/22/2014)... activity of babies in developing countries could be ... of cognitive dysfunction, using a new technique piloted ... function of infants can be visualised and tracked ... the method, called functional near infra-red spectroscopy (fNIRS), ... relied upon for decades. , Professor Clare ...
(Date:4/21/2014)... 21, 2014 Performing brain research that can one ... of Houston (UH) junior Khanh (Kate) Nguyen has been ... A double major in mathematics and physics, Nguyen is ... Scholarship. , One of the most prestigious awards ... to sophomore and junior students majoring in mathematics, the ...
Breaking Biology News(10 mins):NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 2NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 3First brain images of African infants enable research into cognitive effects of nutrition 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4
... and females of all ages were tested for their ability ... different concentrations, and then given an overall score for their ... results showed that olfactory function deteriorates relatively slowly with age ... a history of nasal problems such as sinusitis. ...
... The arrival of genetically modified crops has added another ... says a sociocultural anthropologist at Washington University in St. ... and of environmental studies, both in Arts & Sciences, ... first detailed anthropological fieldwork on these crops and the ...
... bronchitis virus (IBV) causes losses of £23.6M a year to ... new way to vaccinate chicks against the disease ?one that ... , A pre-hatching prototype vaccine virus which provides immunity ... for Animal Health (IAH) and vaccine company Intervet UK. It ...
Cached Biology News:New technologies coming too fast for Indian farmers 2In-shell vaccine for chick disease 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: